SystImmune to Present iza‑bren (BL‑B01D1) Phase II ES‑SCLC Data at ELCC 2026

SystImmune announced that safety and efficacy results for iza‑bren (izalontamab brengitecan) in combination with serplulimab in treatment‑naïve extensive‑stage small cell lung cancer (ES‑SCLC) will be presented at ELCC 2026; the presentation is listed as a Phase II study. The company stated that safety and efficacy results from this regimen will be disclosed at the meeting.

In the announcement, SystImmune characterizes the regimen as iza‑bren given with serplulimab in treatment‑naïve ES‑SCLC. The company’s Chief Medical Officer, Jonathan Cheng, MD, is quoted as saying the team is “encouraged by the safety and efficacy signals observed” with the combination in this group.

The release also situates the ES‑SCLC presentation within previously reported clinical activity for iza‑bren in other tumor types, specifically naming lung, breast, and bladder cancer patients. These earlier data are described as having been presented at ASCO, ESMO, WCLC, and SABCS across 2023, 2024, and 2025

On partnerships, SystImmune states that iza‑bren is “jointly developed by SystImmune and Bristol Myers Squibb” under a “collaboration and exclusive license agreement in territories outside of China.” In the same remarks, company leadership links the ES‑SCLC experience to forward-looking development intent, stating that the findings “support further exploration of iza‑bren–based combinations in earlier lines of therapy.”